SCHEMBL25834954

SCHEMBL25834954

CC(C)OCCCC(=O)NCCOCCOc1ccc(-c2nnc(C(C)C)o2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
MAPT P10636 4/20 0.41
HPGD P15428 3/20 0.41
ALOX15 P16050 2/20 0.41
TSHR P16473 2/20 0.41
NR1H4 Q96RI1 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
SMPD1 P17405 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GLA P06280 1/20 0.36
HTT P42858 1/20 0.36
HDAC8 Q9BY41 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26034354 0.89 ATM (0.43) ATMMAPTHPGDALOX15TSHR
SCHEMBL25834864 0.86 TP53 (0.42) ATMMAPTHPGDALOX15TSHR
SCHEMBL25834990 0.86 ATM (0.41) ATMMAPTHPGDALOX15TSHR
SCHEMBL25836929 0.82 ATM (0.45) ATMMAPTHPGDALOX15TSHR
SCHEMBL25834802 0.79 ATM (0.45) ATMMAPTHPGDALOX15TSHR
SCHEMBL24340634 0.77 HPGD (0.48) MAPTHPGDALOX15TSHRGAA
SCHEMBL25835010 0.77 ALDH1A1 (0.48) MAPTHPGDTSHRNR1H4SMN1; SMN2
SCHEMBL24340752 0.75 MAPT (0.44) MAPTHPGDALOX15TSHRNR1H4
SCHEMBL24164860 0.74 MEN1 (0.58) ATMHPGDALOX15TSHRGAA
SCHEMBL24340753 0.74 MAPT (0.43) MAPTHPGDALOX15TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 ATM 2852/4885MAPT 3973/4885HPGD 2974/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 ATM 2775/4885MAPT 4094/4885HPGD 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.